| Literature DB >> 33806103 |
S A Antonov1, E V Novosadova1.
Abstract
Human induced pluripotent stem (iPS) cells have the potential to give rise to a new era in Parkinson's disease (PD) research. As a unique source of midbrain dopaminergic (DA) neurons, iPS cells provide unparalleled capabilities for investigating the pathogenesis of PD, the development of novel anti-parkinsonian drugs, and personalized therapy design. Significant progress in developmental biology of midbrain DA neurons laid the foundation for their efficient derivation from iPS cells. The introduction of 3D culture methods to mimic the brain microenvironment further expanded the vast opportunities of iPS cell-based research of the neurodegenerative diseases. However, while the benefits for basic and applied studies provided by iPS cells receive widespread coverage in the current literature, the drawbacks of this model in its current state, and in particular, the aspects of differentiation protocols requiring further refinement are commonly overlooked. This review summarizes the recent data on general and subtype-specific features of midbrain DA neurons and their development. Here, we review the current protocols for derivation of DA neurons from human iPS cells and outline their general weak spots. The associated gaps in the contemporary knowledge are considered and the possible directions for future research that may assist in improving the differentiation conditions and increase the efficiency of using iPS cell-derived neurons for PD drug development are discussed.Entities:
Keywords: differentiation; dopamine neurons; drug screening; induced pluripotent stem cells; parkinson’s disease
Year: 2021 PMID: 33806103 PMCID: PMC8037675 DOI: 10.3390/ijms22073381
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The general differentiation sequence of human iPS cells into the midbrain DA neurons. The crucial stages of in vitro differentiation protocols are shown by black arrows with small molecules and growth factors for inducing the neural lineage progression listed above. Grey arrows show potential routes for generation of pure or enriched cultures of specific midbrain DA neuron subtypes. Question signs indicate processes proceeding in vitro in uncontrolled/autonomous manner through unknown mechanisms highlighted in the red boxes; understanding of these mechanisms is critical for overcoming heterogeneity and asynchronicity of neuronal differentiation of iPS cells. The suggestions for optimizing or refining the differentiation conditions are shown in the green boxes. Withdrawal of iPS cells from self-renewing conditions and their treatment with TGFβ antagonists either in monolayer culture or in suspension EBs induces the differentiation of early multipotent NPC (A). After isolation and expansion, these cells are regionalized into the midbrain floor plate NPC (B) through activation of Hedgehog, Wnt and FGF8 signaling. While several commercially available small molecules can efficiently substitute recombinant Shh and Wnt1/Wnt5a, no FGF8 mimetics have been developed to date. Alternatively, midbrain floor plate NPC can be directly obtained from iPS cells by the overexpression of Lmx1a, Foxa2 and Nurr1, and other midbrain-specific TF genes. (C) Generation and (D) functional maturation of post-mitotic DA neurons are performed by their continuous maintenance in presence of neurotrophic factors BDNF and GDNF, and optionally dibutyril cAMP (dBcAMP) and Notch antagonists (e.g., DAPT) to promote their survival and differentiation. However, due to the lack of control over these processes the resulting cell populations are heterogenous, consisting of neural progenitors and different DA neuron subtypes at various stages of maturation. The development of small molecule mimetics of FGF8, BDNF and GDNF proteins would be beneficial for reducing the costs of generation of iPS cell-derived neurons. The generation of floor plate progenitor subtypes (E) can be potentially carried out by employing selective growth factor-based conditions, forced expression of subtype-specific TFs or isolation from mixed cultures by FACS. These progenitor subtypes could be further differentiated into corresponding subtypes of post-mitotic DA neurons (F). Alternatively, pure or enriched cultures of A9 and other midbrain DA neuron subtypes could be obtained by their isolation from mixed DA neuron cultures using FACS at the terminal differentiation stage. The detailed description of each stage is provided in the text. BDNF—brain derived neurotrophic factor, GDNF—glial cell derived neurotrophic factor, FGF8—fibroblast growth factor 8, FGF20—fibroblast growth factor 20; Puro—puromorphamine, RA—retinoic acid, Shh—sonic hedgehog.
Figure 2In vitro studies based on human iPS cell-derived DA neurons. Drug development and disease modeling with these cells represent rapidly advancing fields of modern research. The personalized therapy is a perspective area for future studies relying on patient-specific neurons, but due to paucity of currently available treatment options for PD and absence of approved targeted drugs it was not implemented into the practice to date.
The list of currently available iPS cell lines derived from donors with different forms of hereditary PD.
| Gene | Mutation | Reference |
|---|---|---|
|
| R258Q | Vanhauwaert [ |
|
| Gene triplication | Devine [ |
| A53T | Chung [ | |
|
| G2019S | Tolosa [ |
| R1441C | Cooper [ | |
| R1441G | Hsieh [ | |
| Y1699C | ||
|
| V324A | Chung [ |
| Exon 2 deletion | Shuvalova [ | |
| Exon 3 deletion/R42P | Zhong [ | |
| Exon 3 and/or 4 deletion | Shaltouki [ | |
| Exon 3 and/or 5 deletion | Jiang [ | |
| Homozygous exon 3 deletion | Zhong [ | |
| Compound heterozygous deletion of exones 3 and 5 | Zhong [ | |
| Exon 2–4 and/or 6–7 deletion | Imaizumi [ | |
|
| Q456X | Chung [ |
| V170G | Rakovic [ | |
| I368N | Abdul [ | |
|
| E64D | Burbulla [ |
|
| N370S | Novosadova [ |
| L444P | Schöndorf [ | |
| G2019S in LRRK2 and N370S in GBA genes | Novosadova [ | |
| Sporadic PD | Novosadova [ |